XOMA vs. VNDA, EBS, VSTM, MACK, RIGL, SYRS, RGLS, LXRX, CUE, and OPK
Should you be buying XOMA stock or one of its competitors? The main competitors of XOMA include Vanda Pharmaceuticals (VNDA), Emergent BioSolutions (EBS), Verastem (VSTM), Merrimack Pharmaceuticals (MACK), Rigel Pharmaceuticals (RIGL), Syros Pharmaceuticals (SYRS), Regulus Therapeutics (RGLS), Lexicon Pharmaceuticals (LXRX), Cue Biopharma (CUE), and OPKO Health (OPK). These companies are all part of the "pharmaceutical preparations" industry.
Vanda Pharmaceuticals (NASDAQ:VNDA) and XOMA (NASDAQ:XOMA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, community ranking, earnings, risk and media sentiment.
Vanda Pharmaceuticals has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, XOMA has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.
Vanda Pharmaceuticals has higher revenue and earnings than XOMA. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than XOMA, indicating that it is currently the more affordable of the two stocks.
In the previous week, Vanda Pharmaceuticals had 1 more articles in the media than XOMA. MarketBeat recorded 3 mentions for Vanda Pharmaceuticals and 2 mentions for XOMA. XOMA's average media sentiment score of 0.88 beat Vanda Pharmaceuticals' score of -0.28 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.
Vanda Pharmaceuticals received 104 more outperform votes than XOMA when rated by MarketBeat users. Likewise, 68.55% of users gave Vanda Pharmaceuticals an outperform vote while only 65.95% of users gave XOMA an outperform vote.
88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.9% of XOMA shares are owned by institutional investors. 7.7% of Vanda Pharmaceuticals shares are owned by insiders. Comparatively, 7.2% of XOMA shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Vanda Pharmaceuticals has a net margin of -2.75% compared to Vanda Pharmaceuticals' net margin of -705.23%. XOMA's return on equity of -0.90% beat Vanda Pharmaceuticals' return on equity.
XOMA has a consensus target price of $57.00, suggesting a potential upside of 123.44%. Given Vanda Pharmaceuticals' higher probable upside, analysts clearly believe XOMA is more favorable than Vanda Pharmaceuticals.
Summary
Vanda Pharmaceuticals beats XOMA on 12 of the 17 factors compared between the two stocks.
Get XOMA News Delivered to You Automatically
Sign up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XOMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
